References
- Van Acker H, Capsomidis A, Smits EL, Van Tendeloo VF. CD56 in the immune system: more than a marker for cytotoxicity? Front Immunol 2017; 8: 892–90. doi: 10.3389/fimmu.2017.00892
- Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. WHO classification of tumours of hematopoietic and lymphoid tissues. 4th edition. Lyon: IARC; 2017.
- Chang H, Samiee S, Yi QL. Prognostic relevance of CD56 expression in multiple myeloma: a study including 107 cases treated with high-dose melphalan-based hemotherapy and autologous stem cell transplant. Leuk Lymphoma 2006; 47: 43–7. doi: 10.1080/10428190500272549
- Chaudhri NA, Almhareb F, Walter CU, Nounou R, Khalil S, Bakshi N, et al. Expression of CD56 in acute myeloid leukemia (AML) is associated with poor outcome when patients treated with stem cell transplant in second remission but not in the first remission. Blood 2011; 118: 4880–86. doi: 10.1182/blood.V118.21.4880.4880
- Ravandi F, Cortes J, Estrov Z, Thomas D. CD56 expression predicts occurrence of CNS disease in acute lymphoblastic leukaemia. Leuk Res 2002; 26: 643–49. doi: 10.1016/s0145-2126(01)00188-6
- Grimma KE, O’Malley DP. Aggressive B cell lymphomas in the 2017 revised WHO classification of tumors of hematopoietic and lymphoid tissues. Ann Diagn Pathol 2019; 38: 6–10. doi: 10.1016/j.anndiagpath.2018.09.014
- Feugier P, Van Hoof A, Sebban C, Solal-Celigny P, Bouabdallah R, Fermé C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the group d’Etude des Lymphomes de l’Adulte. J Clin Oncol 2005; 23: 4117–26. doi: 10.1200/JCO.2005.09.131
- Liu Y, Barta SK. Diffuse large B-cell lymphoma: 2019 update on diagnosis, risk stratification and treatment. Am J Hematol 2019; 94: 604–16. doi: 10.1002/ajh.25460
- Gomyo H, Kajimoto K, Miyata Y, Maeda A, Mizuno I, Yamamoto K, et al. CD56-positive diffuse large B-cell lymphoma: possible association with extranodal involvement and bcl-6 expression. Hematology 2010; 15: 157–61. doi: 10.1179/102453309X12583347113573
- Gu MJ, Ha JO. CD56 positive diffuse large B-cell lymphoma: a case report and literature review. Int J Clin Exp Pathol 2013; 6: 3023–25.
- Weisberger J, Gorczyca W, Kinney MC. CD56-Positive Large B-cell Lymphoma. App Imm Mol Morphol 2007; 14: 369–74. doi: 10.1097/01.pai.0000208279.66189.43
- Stacchini A, Barreca A, Demurtas A, Aliberti S, di Celle PF, Novero D. Flow cytometric detection and quantification of CD56 (neural cell adhesion molecule, NCAM) expression in diffuse large B cell lymphomas and review of the literature. Histopathology 2012; 60: 452–59. doi: 10.1111/j.1365-2559.2011.04098.x
- Isobe Y, Sugimoto K, Takeuchi K, Ando J, Masuda A, Mori T, et al. Neural cell adhesion molecule (CD56)-positive B-cell lymphoma. Eur J Haematol 2007; 79: 166–9. doi: 10.1111/j.1600-0609.2007.00893.x
- Otsuka M, Yakushijin Y, Hamada M, Hato T, Yasukawa M, Fujita S. Role of CD21 antigen in diffuse largeB-cell lymphoma and its clinical significance. Br J Hematol 2004; 127: 416–24. doi: 10.1111/j.1365-2141.2004.05226.x
- Hammer RD, Vnencak-Jones CL, Manning B, Glick AD, Kinney MC. Microvillus lymphomas are B-cell neoplasms that frequently express CD56. Mod Pathol 1998; 11: 239–46. PMID: 9521469
- Chen B, Sun WY, Zhang G. [CD56 positive diffuse large B-cell lymphoma: report of a case]. [Chinese]. Zhonghua Bing Li Xue Za Zhi 2010; 39: 343–4. PMID: 20654160
- Muroi K, Omine K, Kuribara R, Uchida M, Izumi T, Hatake K, et al. CD56 expression in B-cell lymphoma. Leuk Res 1998; 22: 201–2. doi: 10.1016/s0145-2126(97)00153-7
- Sekita T, Tamaru J, Isobe K, Harigaya K, Masuoka S, Katayama T, et al. Diffuse large B-cell lymphoma expressing the natural killer cell marker CD56. Pathol Int 1999; 49: 752–8. doi: 10.1046/j.1440-1827.1999.00929.x
- Boltezar L, Kloboves-Prevodnik V, Pohar-Perme M, Gasljevic G, Jezersek-Novakovic B. Comparison of the algorithms classifying the ABC and GCB subtypes in diffuse large B-cell lymphoma. Oncol Lett 2018; 15: 6903–12. doi: 10.3892/ol.2018.8243
- Brozic A, Pohar Marinsek Z, Novakovic S, Kloboves-Prevodnik V. Inconclusive flow cytometric surface light chain results; can cytoplasmic light chains, Bcl-2 expression and PCR clonality analysis improve accuracy of cytological diagnoses in B-cell lymphomas? Diagn Pathol 2015; 10: 191–6. doi: 10.1186/s13000-015-0427-5
- Crotty R, Hu K, Stevenson K, Pontius MY, Sohani AR, Ryan RJH, et al. Simultaneous identification of cell of origin, translocations, and hotspot mutations in diffuse large B-cell lymphoma using a single RNA-sequencing assay. Am J Clin Pathol 2021; 155: 748–54. doi: 10.1093/ajcp/aqaa185
- Mokánszki A, Bicskó R, Gergely L, Méhes G. Cell-free total nucleic acid-based genotyping of aggressive lymphoma: Comprehensive analysis of gene fusions and nucleotide variants by next-generation sequencing. Cancers 2021; 13: 3032. doi: 10.3390/cancers13123032
- Kern WF, Spier CM, Miller TP, Grogan TM. NCAM (CD56)-positive malignant lymphoma. Leuk Lymphoma 1993; 12: 1–10. doi: 10.3109/10428199309059565
- Kirpatrik D, Swalling A, Kasmeridis H, Farshid G. Metastatic neuroendocrine carcinoma negative for cytokeratin immunohistochemistry. Pathology 2017; S1: S140–S141. doi: 10.1016/j.pathol.2016.09.057
- Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004; 103: 275–82. doi: 10.1182/blood-2003-05-1545
- Shiozawa E, Yamochi-Onizuka T, Takimoto M, Ota H. The GCB subtype of diffuse large B-cell lymphoma is less frequent in Asian countries. Leuk Res 2007; 31: 1579–83. doi: 10.1016/j.leukres.2007.03.017
- Rutishauer U, Acheson A, Hall AK, Mann DM, Sunshine J. The neural adhesion molecule (NCAM) as a regulator of cell-cell interactions. Science 1988; 240: 53–7. doi: 10.1126/science.3281256
- Lanier LL, Chang C, Azuma M, Ruitenberg JJ, Hemperly JJ, Phillips JH. Molecular and functional analysis of human natural killer cell-associated neural cell adhesion molecule (N-CMCD56). J Immunol 1991; 146: 4421–26.
- Young HE, Steele TA, Bray RA, Detmer K, Blake LW, Lucas PW, et al. Human pluripotent and progenitor cells display cell surface cluster differentiation markers CD10, CD13, CD56, and MHC class-I. Proc Soc Exp Biol Med 1999; 221: 63–71. doi: 10.1046/j.1525-1373.1999.d01-55.x
- Navarrete M, Oppezzo P. The pathogenesis of follicular lymphoma beyond apoptosis resistance. Trans Canc Res 2017; 6: S529–S532. doi: 10.21037/tcr.201
- Ziepert M, Hasenclever D, Kuhnt E, Glass B, Schmitz N, Pfreundschuh M, et al. Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era. J Clin Oncol 2010; 28: 2373–80. doi: 10.1200/JCO.2009.26.2493
- Schmitz R, Wright GW, Huang DW, Johnson CA, Phelan JD, Wang JQ, et al. Genetics and pathogenesis of diffuse large B-cell lymphoma. NEJM 2018; 378: 1396–407. doi: 10.1056/NEJMoa1801445.
- Shah MH, Lorigan P, O’Brien MER, Fossella FV, Moore KN, Bhatia S, et al. Phase I study of IMGN901, a CD56-targeting antibody-drug conjugate, in patients with CD56-positive solid tumours. Invest New Drugs 2016; 34: 290–99. doi: 10.1007/s10637-016-0336-9.
- 34.
Crossland DL, Denning WL, Ang S, Olivares S, Mi T, Switzer K, et al. Antitumor activity of CD56-chimeric antigen receptor T cells in neuroblastoma and SLCL models. Oncogene 2018; 37: 3686–97. doi:10.1038/s41388-018-0187-2
CrosslandDL DenningWL AngS OlivaresS MiT SwitzerK Antitumor activity of CD56-chimeric antigen receptor T cells in neuroblastoma and SLCL models Oncogene 2018 37 3686 97 10.1038/s41388-018-0187-2